Studies have found that strong PD-L2 expression in a variety of tumor tissues can play a negative role in tumor immune escape and predict poor overall survival, such as in liver cancer 22, esophageal cancer 23, prostate cancer 24, bladder cancer 25 and lung adenocarcinoma 26. This evidence concerns the gene PDCD1LG2 and lung adenocarcinoma.